232 related articles for article (PubMed ID: 20889555)
1. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM; Zehnbauer B; Wilson JA; Baak R; Babic N; Bettinotti M; Buller A; Butz K; Campbell M; Civalier C; El-Badry A; Farkas DH; Lyon E; Mandal S; McKinney J; Muralidharan K; Noll L; Sander T; Shabbeer J; Smith C; Telatar M; Toji L; Vairavan A; Vance C; Weck KE; Wu AH; Yeo KT; Zeller M; Kalman L
J Mol Diagn; 2010 Nov; 12(6):835-46. PubMed ID: 20889555
[TBL] [Abstract][Full Text] [Related]
2. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM; Everts RE; Aggarwal P; Beyer BN; Broeckel U; Epstein-Baak R; Hujsak P; Kornreich R; Liao J; Lorier R; Scott SA; Smith CH; Toji LH; Turner A; Kalman LV
J Mol Diagn; 2016 Jan; 18(1):109-23. PubMed ID: 26621101
[TBL] [Abstract][Full Text] [Related]
3. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing.
Wu AH
Arch Pathol Lab Med; 2013 Sep; 137(9):1232-6. PubMed ID: 23991737
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project.
Pratt VM; Turner A; Broeckel U; Dawson DB; Gaedigk A; Lynnes TC; Medeiros EB; Moyer AM; Requesens D; Vetrini F; Kalman LV
J Mol Diagn; 2021 Aug; 23(8):952-958. PubMed ID: 34020041
[TBL] [Abstract][Full Text] [Related]
5. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project.
Gaedigk A; Turner A; Everts RE; Scott SA; Aggarwal P; Broeckel U; McMillin GA; Melis R; Boone EC; Pratt VM; Kalman LV
J Mol Diagn; 2019 Nov; 21(6):1034-1052. PubMed ID: 31401124
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project.
Gaedigk A; Boone EC; Turner AJ; van Schaik RHN; Chernova D; Wang WY; Broeckel U; Granfield CA; Hodge JC; Ly RC; Lynnes TC; Mitchell MW; Moyer AM; Oliva J; Kalman LV
J Mol Diagn; 2023 Sep; 25(9):655-664. PubMed ID: 37354993
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
10. Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It mutation detection assays.
Melis R; Lyon E; McMillin GA
Expert Rev Mol Diagn; 2006 Nov; 6(6):811-20. PubMed ID: 17140368
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Reference Materials for TPMT and NUDT15: A GeT-RM Collaborative Project.
Pratt VM; Wang WY; Boone EC; Broeckel U; Cody N; Edelmann L; Gaedigk A; Lynnes TC; Medeiros EB; Moyer AM; Mitchell MW; Scott SA; Starostik P; Turner A; Kalman LV
J Mol Diagn; 2022 Oct; 24(10):1079-1088. PubMed ID: 35931342
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
14. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH; Lin CT; Wu YJ; Wu LS
J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387
[TBL] [Abstract][Full Text] [Related]
15. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
Sistonen J; Fuselli S; Palo JU; Chauhan N; Padh H; Sajantila A
Pharmacogenet Genomics; 2009 Feb; 19(2):170-9. PubMed ID: 19151603
[TBL] [Abstract][Full Text] [Related]
18. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.
Azarpira N; Namazi S; Hendijani F; Banan M; Darai M
Pharmacol Rep; 2010; 62(4):740-6. PubMed ID: 20885015
[TBL] [Abstract][Full Text] [Related]
19. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
20. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.
de Leon J; Armstrong SC; Cozza KL
Psychosomatics; 2006; 47(1):75-85. PubMed ID: 16384813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
